Please select the option that best describes you:
What is the preferred second-line therapy for HER2-positive patients with esophageal squamous cell carcinoma who have progressed on first line Trastuzumab and Immunotherapy?
Answer from: Medical Oncologist at Community Practice
I'm assuming we are talking about HER2+ esophageal adenocarcinoma? If that's the case, 2L T-DXd is the way to go. After confirmation of persistent HER2 expression (ctDNA showing positive amplification or rebiopsy with IHC). DESTINY-Gastric04 confirmed the superiority of T-DXd over PAC/RAM in 2L.If y...
Sign In or Register to read more
Answer from: Medical Oncologist at Academic Institution
HER2 overexpression in esophageal squamous cell carcinoma (ESCC) is relatively uncommon compared with gastric or gastroesophageal junction adenocarcinoma. Published estimates suggest that approximately 5–10% of ESCC cases are HER2-positive (Egebjerg et al., PMID 33865993; Rong et al., PMID 322...